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ABSTRACT: Despite efforts to develop new antibiotics, antibacterial resistance still develops too fast for drug discovery to keep
pace. Often, resistance against a new drug develops even before it reaches the market. This continued resistance crisis has
demonstrated that resistance to antibiotics with single protein targets develops too rapidly to be sustainable. Most successful long-
established antibiotics target more than one molecule or possess targets, which are encoded by multiple genes. This realization has
motivated a change in antibiotic development toward drug candidates with multiple targets. Some mechanisms of action presuppose
multiple targets or at least multiple effects, such as targeting the cytoplasmic membrane or the carrier molecule bactoprenol
phosphate and are therefore particularly promising. Moreover, combination therapy approaches are being developed to break
antibiotic resistance or to sensitize bacteria to antibiotic action. In this Review, we provide an overview of antibacterial multitarget
approaches and the mechanisms behind them.
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Antimicrobial resistance has developed into a globalhealthcare crisis that has culminated in the emergence
of multidrug-resistant bacteria that are no longer treatable with
any common antibiotic.1 For example, recently emerging
Neisseria gonorrhoeae strains resistant to third-generation
carbapenems led to a number of untreatable gonorrhea
infections in the UK.2 Despite considerable investments, the
development of innovative, resistance-breaking antibiotics still
progresses too slowly.3,4 For a long time, antibiotics with one
specific protein target were highly sought after in drug design
and screening efforts. Single target drugs were propagated as
the ideal antibiotics with the argument that a high target
specificity equals less side effects. This resulted in a
predominantly genomic-driven approach to antibiotic discov-
ery, where single protein targets were evaluated, while
compounds with multiple or complex targets were regarded
to be unspecific and unsuitable for further development.
However, the last decades have shown that resistance to
antibiotics with specific single protein targets develops too fast
to be sustainable, and the realization emerged that candidates
with multiple targets are worth pursuing for their slower
resistance development rates.5−7 In fact, long-established
antibiotic drugs with great clinical success rarely target only
one specific molecule. For example, β-lactam antibiotics
typically target more than one transpeptidase, and quinolones
inhibit both topoisomerases II and IV.8,9 Antibiotics that truly
have one single protein target, such as sulfonamides targeting
an enzyme involved in folate synthesis or rifampicin targeting
RNA polymerase, are famous for high resistance development
and are therefore usually administered in combination
regimes.10,11
Naturally occurring antibiotics often do not have strict single
targets either. The most common class of natural antimicrobial
substances are antimicrobial peptides, which occur in virtually
all organisms. These molecules predominantly target complex
bacterial structures, e.g., the cell membrane, the cell wall, or
both.12,13 Moreover, antibiotic producers often produce a mix
of structurally related compounds. This is, for example, the
case for gramicidin (contain gramicidin A−C), tyrothricin
(contains gramicidin A−C and tyrocidine A−D), and
polymyxins (contains multiple peptides with small structural
variations depending on the polymyxin type).14,15 Such small
structural variations can result in slightly different target
interactions16−20 and may complicate resistance development
by target alterations and antibiotic-cleaving or scavenging
molecules. Naturally occurring mixes have been used in clinical
settings with great success and in some cases are combined
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with each other or other antibiotics like neomycin.21,22 It is
quite common in clinical practice to use antibiotic combina-
tions for different reasons. For example, trimethoprim is
combined with sulfonamides to prevent quick resistance
development by a single target mutation, and erythromycin
is often given together with penicillin for their synergistic
effect.23 Since more and more pathogens become resistant to
individual antibiotics, it has become pivotal to thoroughly
explore multitarget approaches to combat resistant bacteria. In
this Review, we provide an overview of multitarget antibiotics
and combination approaches that are in current clinical use or
have a chance to be applied in clinical settings in the future.
■ PART 1: MULTITARGET COMPOUNDS
Generally, the ability of a single drug to interact with more
than one specific target is called polypharmacology.24 When
talking about multitarget antibiotics, we distinguish between
different levels of multitargeting. In this Review, we use the
terminology intrinsically multi-effective, multitarget, and multi-
functional. Intrinsically multi-effective compounds may have a
single target, but this molecule or structure is involved in
multiple processes, which are all affected by its inhibition.
Multitarget antibiotics can be divided into multitarget
compounds that target more than one isoenzyme or closely
related proteins of the same pathway and multitarget
compounds that bind to different molecules involved in
separate cellular processes. Multifunctional compounds have a
direct antibiotic target but an additional indirect antibacterial
activity, e.g., immunomodulatory properties. Table 1 gives an
overview of prominent antibiotics of these categories that are
used in the clinic.
Intrinsically Multi-effective. The most common anti-
microbial target, whose inhibition results in a multitude of
cellular effects, is the cytoplasmic membrane. It is the target of
many natural antibiotics, most prominently host defense
peptides.12 The cytoplasmic membrane harbors essential
cellular processes, such as the respiratory chain and cell wall
synthesis (Figure 1A), and many more important components,
including nutrient uptake, secretion, and stress response
systems. Thus, membrane-targeting antibiotics have the
potential to (i) inhibit processes essential for survival, (ii)
reduce bacterial fitness, (iii) impair virulence, and (iv) interfere
with stress adaptation. Depending on how an antibiotic
interferes with the membrane, few or a whole array of
membrane-bound processes can be affected.20 Several
membrane-active antibiotics are used in the clinic, although
only a handful are applied systemically. For some of them, their
multiple effects on bacterial cells have been studied.
Many membrane-active antibiotics dissipate the membrane
potential. This depolarization has a number of downstream
effects due to the depletion of ATP and the subsequent
impairment of ATP-dependent processes. Moreover, it leads to
the displacement of peripheral membrane proteins that bind to
the membrane surface by electrostatic interactions, such as the
Table 1. Examples for Clinically Used Antibiotics with Multiple Mechanisms of Action
antibiotic targets mechanism of action ref
Intrinsically Multi-effective
daptomycin phosphatidylglycerol,
fluid lipid domains
binds to phosphatidylglycerol, inserts into fluid lipid domains that harbor the cell wall synthesis
machinery, immediately inhibits cell wall and membrane synthesis; prolonged treatment results in
partial membrane depolarization and impairs several other membrane-bound processes
25, 26
gramicidin S membrane induces membrane phase separation causing inhibition of cell envelope synthesis and cell division 20
vancomycin lipid II binds to lipid II, thereby inhibits peptidoglycan synthesis and depletes the pool of bactoprenol
phosphate, additionally resulting in the inhibition of wall teichoic acid synthesis
27, 28
bacitracin bactoprenol
pyrophosphate
depletes the pool of bactoprenol phosphate resulting in inhibition of peptidoglycan and wall teichoic acid
synthesis
29
nitrofurantoin cellular
macromolecules
generates reactive oxygen species, which damage cellular macromolecules including DNA and membrane
lipids
30, 31
acyldepsipeptides Clp protease deregulates the Clp protease resulting in unspecific degradation of a variety of proteins 32, 33
bedaquiline ATP synthase inhibits ATP synthase, depleting the ATP pool and resulting in the inhibition of all energy-consuming
cellular processes
34
Multitarget
penicillin penicillin-binding
proteins
inhibits multiple penicillin-binding proteins 8
ciprofloxacin topoisomerase II and
IV
inhibits topoisomerase II and IV 9
tetracycline ribosome and
membrane
blocks attachment of loaded aminoacyl tRNA to the A-site of the ribosome; also impairs membrane
function
31, 35
polymyxin B outer and inner
membrane
permeabilizes both the outer and inner membrane of Gram-negative bacteria 36
tyrocidine membrane and
probably DNA
forms defined ion-conducting membrane pores; probably additionally binds to DNA 20, 37,
38
Multifunctional
clindamycin 50S rRNA anti-inflammatory 39, 40
clofazimine guanine anti-inflammatory 41−43
dapsone dihydropteroate
synthase
anti-inflammatory and immunomodulatory 44, 45
macrolides 50S rRNA anti-inflammatory and immunomodulatory 46−48
metronidazole DNA anti-inflammatory 49, 50
rifampicin DNA-dependent RNA
polymerase
anti-inflammatory and immunomodulatory 51, 52
tetracycline ribosome and
membrane
anti-inflammatory 53−55
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Review
https://dx.doi.org/10.1021/acsinfecdis.0c00001
ACS Infect. Dis. 2020, 6, 1346−1365
1347
cell division proteins FtsA and MinD.56,57 However, not all
membrane effects can be explained by membrane depolariza-
tion. Thus, the membrane pore-forming peptides tyrocidine A
and C not only dissipate the membrane potential and lead to
leakage of ions and small molecules but also reduce membrane
fluidity, diminish membrane domains, and affect the local-
ization of several membrane-bound processes, including cell
division, peptidoglycan synthesis, phospholipid synthesis,
respiration, and ATP synthesis.20 Such effects are not observed
when the membrane potential is dissipated by specific
ionophores.56,57 The structurally similar peptide gramicidin S,
which does not form distinct membrane pores and has milder
effects on membrane potential and fluidity, only affects cell
division and cell envelope synthesis proteins.20,58 Daptomycin,
which is one of the few systemically applied membrane-
targeting antibiotics, has recently been described to interfere
with both peptidoglycan and phospholipid synthesis by
interfering with fluid membrane microdomains that harbor
the lateral cell wall synthesis machinery.25,31,59
Similar results have been obtained for host defense peptides
and experimental compounds that are not yet in clinical
application. For example, human β-defensin 3 forms a dimeric
raft-like structure with two α-helices anchoring it to the
hydrocarbon layer and binds to negatively charged lipid head
goups.60 It has also been shown to bind the cell wall precursor
lipid II with low affinity, probably due to electrostatic
interactions with the pyrophosphate group.61 Thus, the
defensin is attracted to sites of active cell division and cell
wall synthesis, where its presence disturbs the interactions of
the complex peptidoglycan synthetic machinery, which was
coined the “sand in the gearbox” effect.61 The structurally
similar human β-defensin 2 binds to distinct membrane foci at
nascent cell division septa, where it disturbs the function of
SecA and sortase A, which specifically localize to these sites
Figure 1. Examples for multiple mechanisms of action of antibiotics. (A−C) Antibiotics with intrinsically multi-effective properties. (A) Disrupting
cytoplasmic membrane integrity, e.g., by gramicidin S, affects membrane-bound processes, most prominently respiration and lipid II synthesis. (B)
Binding of antibiotics to lipid II or its carrier molecule undecaprenyl(pyro)phosphate (here: bacitracin binding UDP-PP) depletes the carrier pool,
affecting both the synthesis of wall teichoic acids (WTA) and lipid II. (C) Inhibition of ATP synthase, e.g., by bedaquiline, leads to the depletion of
the cellular ATP pool and thus inhibition of multiple metabolic processes. (D−F) Antibiotics with multiple targets. (D) β-Lactams (here
imipenem) typically inhibit more than one penicillin-binding protein (PBP). (E) Polymyxins like polymyxin B or colistin disrupt both the outer and
inner membrane of Gram-negative bacteria. (F) Type A lantibiotics like nisin bind to lipid II and use it as a docking molecule to form a
transmembrane pore.
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and are involved in the secretion of virulence factors.62 Other
membrane-active compounds have been observed to have
broader effects. For example, the membrane-disruptive
peptides TC19 and TC84, which are derived from the
microbicidal blood platelet protein thrombocidin,63 lead to
large-scale disruption of membrane organization and affect a
multitude of cellular processes, including cell division,
peptidoglycan synthesis, phospholipid synthesis, respiration,
ATP synthesis, and spore outgrowth.64−66 Such a broad panel
of effects raises the following questions: which ones are due to
the multifaceted mechanisms of the compounds and which are
merely a consequence of cell death? It is therefore pivotal to
examine the mechanism of a compound after short treatment
times with sublethal concentrations.4 The comparison of the
effects observed under these conditions with those occurring at
lethal concentrations or after prolonged treatment can give
insight into which effects lead to cell death and which are a
consequence thereof. In the case of the TC19 and TC84
peptides, membrane depolarization, rigidification, and phase
separation were already observed at sublethal concentrations
and increased at lethal concentrations, while other observa-
tions like protein delocalization and intracellular content
leakage were mainly observed at lethal concentrations or after
prolonged treatment.64,65 This suggests that the primary
mechanism of these peptides is the disruption of membrane
organization. Similarly, depolarization and limited ion leakage
are observed with daptomycin at high concentrations and long
treatment times. However, at inhibitory, and even lethal,
concentrations these effects do not occur, suggesting that
increased membrane permeability is a consequence of cell
death and not the primary mechanism by which it occurs.67
However, broad effects do not necessarily need to be a mere
consequence of membrane disruption. Similar effects have
been achieved by other compounds with quite creative
molecular mechanisms. For example, the cyclic hexapeptide
cWFW induces large-scale phase separation sorting peripheral
and integral membrane proteins into two distinct domains,68
and the plant-derived antibiotic candidate rhodomyrtone forms
large membrane vesicles that irreversibly trap both peripheral
and transmembrane proteins.69
Another molecular target that intrinsically presupposes
multiple effects is the peptidoglycan precursor lipid II, which
is the antibiotic target of the glycopeptide antibiotics
vancomycin, telavancin, oritavancin, dalbavancin, and teicopla-
nin.70−73 Lipid II is also the target of a variety of lantibiotics,
most prominently the food preservative nisin. While nisin and
other type A lantibiotics, such as gallidermin and epidermin,
additionally target the cell membrane,13,74,75 type B lantibiotics
like mersacidin do not seem to have additional membrane
effects.74,76 Though the application of lantibiotics for
antimicrobial coatings, e.g., for implants, is being explored,77
none of them is currently used in a clinical setting. Lipid II is
synthesized in the cytosol and attached to a lipid carrier
molecule, undecaprenol phosphate, yielding the peptidoglycan
building block lipid II. Lipid II flips over the membrane to the
cell surface, and when the building block is incorporated into
the cell wall, undecaprenyl phosphate flips back over the
membrane to the cytosolic side, where it can undergo another
cycle of peptidoglycan synthesis.78 However, undecaprenyl
phosphate is also used in the biosynthesis of wall teichoic acids,
an important component of the Gram-positive bacterial cell
wall.78,79 The binding of antibiotics to lipid II not only directly
prevents the incorporation of peptidoglycan building blocks
into the cell wall but also depletes the undecaprenyl phosphate
pool and thus concomitantly impairs the wall teichoic acid
synthesis. Likewise, compounds that bind undecaprenyl
phosphate (e.g., friulimicin B) or undecaprenol pyrophosphate
(bacitracin) simultaneously inhibit both processes (Figure 1B).
Moreover, cell wall synthesis is coupled to other cellular
processes, most prominently cell division, and the binding of
antibiotics to the sites of cell wall synthesis is likely to have
additional “sand in the gearbox” effects.61 Due to their typically
large size and/or hydrophobic or amphipathic properties,
membrane and cell wall-targeting antibiotics rarely cross the
outer membrane of Gram-negative bacteria and are mostly
used against and studied in Gram-positives. However, the
general principle of the intrinsically multiple effects of such
compounds is the same in all organisms.
These effects have also been predicted for other multiprotein
machineries like the respiratory chain. Indeed, the inhibition of
respiration and/or ATP synthase and subsequent depletion of
ATP pools have been observed for several compounds, whose
primary target is the cell membrane.58,69,80−82 Membrane
potential and respiration are closely intertwined, and the
impairment of one can lead to the inhibition of the other.83,84
Either way, both will have downstream effects on the
performance of ATP synthase and the availability of ATP for
important cellular processes (Figure 1C). Currently, no
respiratory chain inhibitor is available as an antibiotic on the
market, but with bedaquiline, the first ATP synthase inhibitor
was marketed for the treatment of tuberculosis in 2012.34 The
impairment of the electron transport chain can also generate
reactive oxygen species and thus cause oxidative stress.85 This
leads to widespread oxidative damage to cellular macro-
molecules, including DNA, proteins, and the cell membrane.86
Oxidative damage is also a key mechanism of killing
pathogenic bacteria by the immune system that is mediated
by neutrophils.87 While the generation of reactive oxygen
species may be a side effect of membrane-targeting antibiotics,
there is one antibiotic in the clinic that makes targeted use of
oxidative stress. Nitrofurantoin, which is used against urinary
tract infections, is a pro-drug that is activated by cellular
nitrofuran reductases resulting in reactive intermediates that
damage cellular macromolecules, especially DNA.30,31
Another mechanism that should be mentioned in this
category is the deregulation of the ClpP protease by
acyldepsipeptide antibiotics. ClpP takes part in both the
general degradation of misfolded proteins and the regulated
proteolysis of a range of substrates, including transcription
factors and regulatory proteins. Acyldepsipeptides deactivate
the tight control mechanisms that normally ensure that only
such proteins that are either defective or supposed to be
degraded as part of a regulatory cascade are degraded by ClpP.
This leads to the uncontrolled proteolysis of intact cytosolic
proteins and among them the key cell division protein
FtsZ.32,33,88
Translation inhibitors that target the bacterial ribosome
always bind to rRNAs, which are encoded in multiple copies in
the bacterial genome.5,89 While they only have one binding
site, their resistance development rates are reduced, since
simple point mutations are unlikely to affect all gene copies.5
Translation inhibitors are also intrinsically multi-effective
antibiotics, since an impaired ability to produce proteins
hampers multiple cellular processes including the ability to
elicit an appropriate stress response and thus prevents stress
adaptation. Next to β-lactams, ribosome inhibitors constitute
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the most successful antibiotic class in the clinic, underlining
the potential of compounds with multiple targets.
Multiple Targets in the Same Pathway. Most of the
antibiotics described above target one specific cellular
structure, which itself is involved in different processes.
However, there are also several antibiotics that bind to two
or more distinct molecules. We will first discuss those
compounds that target related proteins of the same pathway.
The most extreme examples for this are the β-lactam
antibiotics, which typically target more than one penicillin-
binding protein (PBP) (Figure 1D).8 For example, Escherichia
coli has 8 PBPs, 6 of which are inhibited by penicillin G.90−92
Other examples include quinolone antibiotics, which target
both topoisomerase II and IV involved in DNA supercoiling
and resolving DNA concatemers, respectively,9 and the cell
wall synthesis inhibitors fosfomycin and D-cycloserine. Gram-
positive bacteria possess two copies of MurA, the first enzyme
in the lipid II synthesis pathway, and fosfomycin inhibits both
isoenzymes.93 D-Cycloserine competitively inhibits both
alanine racemase and D-ala-D-ala ligase, which converts L-
alanine to the D-alanine dipeptide that is part of the
peptidoglycan interpeptide bridge.94 Similarly, platencin, a
fatty acid synthesis inhibitor that attracted significant attention
upon its discovery but then encountered several hurdles in
preclinical development,95 is a dual inhibitor of the FabF and
FabH enzymes.96,97
Multiple Targets in Different Pathways. Several anti-
biotics have been found that inhibit two or more distinct
targets that are not closely related components of the same
pathway or process. Not only is it more difficult to acquire
target-based resistance in two different molecules, but also
bacteria need to react with two different stress responses to
mitigate antibiotic action, hampering their capabilities for
efficient stress adaptation; thus, these antibiotics have an
additional advantage.
There are several examples for such compounds in the clinic,
and new molecules with multiple targets are regularly
discovered. One example are the polymyxins, in particular
polymyxin B and colistin, which are used as last resort
antibiotics against multiresistant Gram-negative infections.98
These polypeptides target both the outer and the inner
membrane of Gram-negative bacteria99,100 (Figure 1E).
Another example is clofazimine, which is used to treat
leprosy.101 This antibiotic binds to guanine bases in bacterial
DNA but also increases phospholipase A1 activity, leading to
toxic overproduction of lysophospholipids.102 The atypical
tetracycline chelocardin, which has recently attracted renewed
interest for clinical development,103,104 inhibits the bacterial
ribosome and additionally depolarizes the cytoplasmic
membrane.105 Tetracycline itself, while not leading to
depolarization, has recently been shown to disturb membrane
organization in addition to translation inhibition.31 The same
was observed for anhydrotetracycline, suggesting that this dual
activity could be a general activity of the tetracycline class.31 It
would be reasonable to assume that membrane activity may be
a general consequence of translation inhibition, since
ribosomes associate with the cell membrane to couple
translation to protein secretion.106 However, other ribosome
inhibitors did not visibly disturb the cell membrane, and a
ribosomal protein mutant that diminishes tetracycline binding
to the ribosome showed the same tetracycline-induced
membrane effects as the wild-type.31 These findings suggest
that the membrane activity of tetracycline is independent from
translation inhibition and thus a separate secondary target.
Similarly, tyrocidines, which primarily disrupt cytoplasmic
membrane integrity, have long ago been proposed to bind
DNA as secondary target. This notion, which was derived from
test tube interactions of the peptides with isolated DNA,38 was
only recently supported by in vivo experiments.20
Another very prominent example are antibiotics with a dual
mechanism on cell wall synthesis and the cell membrane. This
is relatively common, since cell wall synthesis inhibitors often
target membrane-bound steps of this pathway. Thus, both
targets are in close proximity. The most prominent example for
this is the lantibiotic nisin, which is not used clinically but is a
common food preservative (Figure 1F). Nisin has a two-step
mechanism of action. It first establishes contact with lipid II,
inhibiting peptidoglycan synthesis. It then inserts into the lipid
bilayer to form a transmembrane pore.107−109 More recently, it
was found that nisin also binds to undecaprenyl phosphate,
adding another structure to its list of molecular targets.110
While nisin is able to bind to negatively charged lipids in the
absence of lipid II or undecaprenyl phosphate,111 it needs the
lipid-coupled cell wall precursor as a docking molecule to form
a transmembrane pore. Other lantibiotics like gallidermin can
impair both targets independently.112 This property of
lantibiotics also inspired the development of dual-function
vancomycin derivatives. Telavancin and oritavancin carry a
hydrocarbon tail, which allows them to insert into the cell
membrane after binding lipid II. Thereby, they disrupt the
permeability barrier, a feature that vancomycin is lacking and
that restores activity against strains with high-level vancomycin
resistance.7,71 Daptomycin could be included in this group as
well, since it likewise inserts into the cell membrane and
impairs cell wall synthesis.25 However, at least to our current
knowledge, it only binds a single molecular target, namely,
phosphatidylglycerol-containing lipids.113−116
Designer Dual-Target Compounds. Inspired by the
clinical success of these multitarget antibiotics, approaches
have been undertaken to develop dual-target molecules. These
can either be stable hybrids combining two functions in one
molecule or cleavable compounds, whereby the prodrug has a
different target than the cleavage product.117,118 In the past,
cleavable compounds have essentially behaved like simple
prodrugs for the cleavage product rather than eliciting their
intended dual effects. Hence, newer efforts rather focus on
Table 2. Antibiotic Hybrid Molecules Currently under Clinical Development
compound antibiotic 1 inhibited process 1 antibiotic 2 inhibited process 2 stage ref
cadazolid quinolone topoisomerases II and IV oxazolidinone translation phase III 122
cefilavancin (TD-1792) vancomycin lipid II cephalosporin PBPs phase III 123
DNV3837 (MCB-3681)a fluoroquinolone topoisomerases II and IV oxazolidinone translation phase II 124
TNP-2092 (CBR-2092) rifamycin RNA polymerase quinolone topoisomerases II and IV phase II 120
TD-1607 glycopeptide lipid II cephalosporin PBPs phase I 125
aMCB-3681 was developed into the prodrug MBB-3837, which was renamed DNV3837 after Morphochem was acquired by Deinove.
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stable hybrids.118−120 These approaches have been recently
reviewed in detail,117,121 but we want to give a brief overview
of the molecules that are currently underway in clinical
development (Table 2).
Cadazolid is a stable hybrid of a quinolone and
oxazolidinone and currently in phase III clinical trials for the
treatment of Clostridium dif f icile infections.122,126 It primarily
inhibits translation but also topoisomerase activity and shows
low resistance development rates.127 Cefilavancin is a stable
hybrid molecule of vancomycin and a third-generation
cephalosporin, which is currently undergoing phase III clinical
trials for complicated skin and soft tissue infections.121 This
hybrid compound is active against both methicillin and
vancomycin-resistant Staphylococcus aureus, yet it has not
been verified to which extent it inhibits lipid II and PBPs.128,129
MCB-3681 is a stable fluoroquinolone−oxazolidinone hybrid
similar to cadazolid.124 It is active against strains that are
resistant to both ciprofloxacin and linezolid.130 MCB-3681 was
scheduled to undergo phase II clinical trials since 2015 and was
granted fast track status by the FDA in 2016.124 Instead, it was
further developed into a prodrug molecule, MCB-3837. In
2018, its developing company Morphochem was acquired by
Deinove, and the compound, now under the name DNV3837,
finally went into phase II clinical trials for treatment of
C. dif f icile infections in 2019.131 The study is planned to be
completed in the summer of 2020.132 TNP-2092 is a stable
rifamycin−quinolone hybrid currently in phase II trials for
prosthetic joint infections.120 It is active against a range of
quinolone and rifamycin-resistant strains.120 TNP-2092 is also
being evaluated against Helicobacter pylori infections yet at a
preclinical stage.133 TD-1607 is a stable glycopeptide−
cephalosporin hybrid similar to cefilavancin. Two phase I
clinical trials have been completed, yet results remain to be
published.121,125
A different hybrid approach was followed by the company
Visterra, who developed an ultranarrow spectrum hybrid
molecule against P. aeruginosa infections by coupling a specific
antibody that targets cell surface glycan molecules with an
antimicrobial peptide.134 Here, the hybrid molecule does not
possess two antibacterial targets, but the antibody strategy
allows more targeted treatment by increasing the local peptide
concentration at the cell surface and bringing the antibiotic
group close to its target.
Another approach to new multifunctional antibiotic
candidates against Gram-negative bacteria based on the
polymyxin lead structure has recently been published.135
These compounds are chimeric peptidomimetics combining
features of polymyxin A with the outer membrane protein-
targeting cyclic peptide murepavadin. They permeabilize the
outer membrane by targeting lipopolysaccharides, inhibit the
outer membrane protein complex Bam, which is involved in
the folding and insertion of β-barrel proteins in the outer
membrane, and permeabilize the inner membrane.135 One of
these compounds is currently undergoing preclinical toxicology
studies.135
It will be exciting to see whether these hybrid molecules will
receive FDA approval and how they will ultimately perform in
the clinic.
Multifunctional Compounds. The last category of
multitarget molecules that we want to discuss are multifunc-
tional compounds, which in addition to their antibacterial
properties possess a second, unrelated activity that is beneficial
for treatment. Most prominently, such compounds may have
anti-inflammatory or immunomodulatory properties (Table 1).
This is well-described for a range of antibiotics, and some are
even used to treat conditions unrelated to infections due to
these properties. This is, for example, the case for macrolides,
which are used to treat diffuse panbronchiolitis,47 dapsone,
which has anti-inflammatory and immunomodulatory effects
and is, for example, used against dermatitis herpetiformis,136 or
rifampicin, used against pruritus caused by primary biliary
cholangitis.137 For other indications, the dual effects of these
compounds are crucial for their therapeutic efficacy. For
example, clindamycin is used to treat acne for both its direct
antibacterial action and its ability to decrease swelling and
inflammation by modulating cytokine production.40,138 Acne is
a very common indication for combining antibacterial and anti-
inflammatory activities. Other antibiotics with this dual
function are metronidazole, tetracycline, macrolides, and
dapsone, which are all used to treat acne.48 Clofazimine,
which is used against leprosy, already has two distinct
antibacterial targets, guanine bases and phospholipase A2.102
In addition to these activities, it also reduces neutrophil
mobility, which is beneficial for treating patients with a type 2
lepra reaction characterized by strong inflammation.139,140 The
range of antibiotics with immunomodulatory and anti-
inflammatory effects and the detailed use of these compounds
have been thoroughly reviewed before48,141−143 and should not
be described here in more detail. However, it should be noted
that daptomycin has been implicated to have immunomodu-
latory effects as well.144 Daptomycin already has multiple
effects on bacterial cells, and both tetracycline and clofazimine
have two distinct antibacterial targets. This illustrates that
multiple activities are quite common in clinically successful
antibiotics.
■ PART 2: ANTIBIOTIC COMBINATIONS
Combination regimes are nowadays quite common in the
clinic, normally to potentiate activity against multiresistant
strains and prevent resistance development. A common regime
is, for example, the combination of sulfonamides with
trimethoprim in urinary tract infections (Figure 2).
Table 3 gives an overview of well-characterized antibiotic
combinations and their effects. A significant amount of
research is being conducted to find combinations that are
more effective than monotherapy or that are resistance-
breaking. When two antibiotics are combined, they are usually
either indifferent in their activity or more effective in killing
Figure 2. Prevention of resistance development by combination
therapy. Sulfonamide antibiotics are typically given together with
trimethoprim to prevent fast target mutation of a single enzyme.
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bacteria due to additive effects. However, if the effects of the
combination exceed the expected additive effects, the
combination is called synergistic. This is, for example, the
case for daptomycin and β-lactams.145 The opposite effect is
called antagonistic and is observed, e.g., with the antifungal
drugs amphotericin B and ravuconazole.146 Synergistic drug
combinations are highly sought after, since they allow one to
lower drug doses and thus may reduce side effects. A different
approach to combination strategies is using potentiators,
sometimes also called antibiotic adjuvants. These are
compounds that by themselves have little or no antibacterial
activity but enhance the effects of antibiotics when
administered in combination. This is, for example, the case
for resistance-breaking compounds like β-lactamase inhib-
itors.147 Such compounds typically target either acquired or
intrinsic antibiotic resistance mechanisms. There have also
been approaches to develop inhibitors of horizontal gene
transfer to prevent the spread of resistance genes.148 In the
following, we will discuss these different approaches to
antibiotic combination therapy.
Antibiotic Synergy. Synergistic compound combinations
are known against Gram-positive and Gram-negative bacteria
and mycobacteria. However, the exact mechanisms of
antibiotic synergy are mostly unknown. While there have
been attempts to explain synergy, these have rarely been
experimentally proven. However, there are four widely
accepted categories of possible synergistic mechanisms for
which examples are known (Figure 3).
One possible synergistic mechanism is the inhibition of the
same target molecule at multiple binding sites (Figure 3A). An
example for this is the synergy of plectasin with teicoplanin and
dalbavancin, which all bind the peptidoglycan precursor lipid
II.167 However, this is not a universal phenomenon, and other
antibiotics that target the same molecule might only have
additive effects. This is, for example, the case for the PBP
inhibitors ampicillin and imipenem.150 Another possibility for
synergy is that two compounds inhibit independent targets in
the same pathway (Figure 3B). This is for example the case for
D-cycloserine, an antituberculosis drug that inhibits an
intracellular step of peptidoglycan synthesis,168 and epigallo-
catechin gallate, a compound found in tea that is thought to
disrupt cell wall peptidoglycan.149,169 Epigallocatechin gallate
also acts synergistically with β-lactam antibiotics149 and
inhibits β-lactamase activity.170 Another example for this
synergistic mechanism is again plectasin, which also acts
synergistically with the glycosyltransferase inhibitor moeno-
mycin.167 However, plectasin does not show synergy with
other cell wall synthesis inhibitors like vancomycin or penicillin
G, demonstrating that the exact mechanisms underlying
synergy are little understood.167 Synergy can also be observed
between compounds that inhibit related processes (Figure
3C). This can often be observed for antibiotics that target cell
wall synthesis and membrane-active compounds, e.g., β-
lactams and daptomycin150,171,172 or the cationic antimicrobial
peptide LL-37 and the lipid II-binding antibiotic teicopla-
nin.173 In some cases, synergy is also observed between
antibiotics with different targets in unrelated pathways as
observed with penicillin and the ribosome inhibitor eryth-
romycin. Here, it has been suggested that the depletion of
penicillin-binding proteins by translation inhibition might be
the underlying mechanism.157 However, a similar combination
of azithromycin (ribosome inhibitor) and imipenem (β-
lactam) only results in additive effects.174 The last documented
mechanism underlying antibiotic synergy is the improvement
of target accessibility (Figure 3D). This is, for example,
observed with the outer membrane-permeabilizing peptide
colistin in combination with drugs that have inner membrane-
bound or cytosolic targets, such as the β-lactam meropenem,
the ribosome inhibitor minocycline, and fosfomycin, which
inhibits the first enzyme in the lipid II pathway.175 This is an
important anti-Gram-negative strategy that will be discussed in
more detail in the following chapter. Antibiotic synergy has
attracted significant attention over the last years, and efforts are
being undertaken to discover new synergistic combinations
that can be useful for clinical applications.176−180
Permeabilizers. In addition to synergistic antibiotic
combinations, potentiative combination approaches have
recently attracted increased attention. Potentiators typically
target intrinsic or acquired antibiotic resistance mechanisms to
sensitize or resensitize bacteria to existing antibiotics (Figure
4).
Table 3. Examples for Well-Characterized Antibiotic Combinationsa
antibiotic 1 antibiotic 2 mechanism of combination ref
synergistic
D-cycloserine inhibits
peptidoglycan synthesis
epigallocatechin gallate binds to and
disrupts the peptidoglycan layer
D-cycloserine inhibits lipid II synthesis, and epigallocatechin gallate disrupts cell wall
peptidoglycan
149
ampicillinb inhibition of
PBPs
daptomycin inhibition of membrane
and cell wall synthesis
daptomycin affects membrane organization, which might interfere with the function of
PBPs; it also inhibits lipid II synthesis by abolishing membrane binding of MurG
25, 150,
151
rifampicinb RNA synthase
inhibition
fusidic acid ribosome inhibition mechanism unknown, but it has been observed in vitro that DNA-dependent RNA-
polymerase is inhibited by the elongation factor T
152−155
erythromycinb ribosome
inhibition
penicillin inhibition of PBPs inhibition of translation might deplete β-lactamases 153, 156,
157
additive
ampicillinb inhibition of
PBPs
imipenem inhibition of PBPs both antibiotics bind to the same site of PBP2A but with low affinity 150, 158,
159
azithromycinb ribosome
inhibition
imipenem inhibition of PBPs inhibition of translation might deplete PBPs, requiring lower doses of imipenem 160, 161
indifferent
sulphamethoxazoleb inhibits
dihydropteroate synthetase
trimethoprim inhibits dihydrofolate
reductase
both compounds target folate synthesis but at different steps; a combination is given to
prevent rapid resistance development to a single drug rather than increase activity
162−164
potentiative
amoxicillineb inhibition of
PBPs
clavulanate β-lactamase inhibitor clavulanate inhibits the β-lactamase that degrades amoxicilline 165, 166
aPBP: penicillin-binding protein. bCombination in clinical use.
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The advantage of these molecules is that they can potentially
increase the activity of a whole array of existing antibiotics.
One class of potentiators are cell envelope permeabilizers,
especially outer membrane-permeabilizing compounds (Figure
4A). These are particularly interesting, since the outer
membrane is the main reason why most antibiotics are
ineffective against Gram-negative bacteria. The inactivation of
this permeability barrier could make almost the whole array of
current antibiotic drugs available for treating these infections,
instead of the handful that we have at our disposal now. Two
antibiotics in current clinical use are known to target the outer
membrane of Gram-negative bacteria, colistin and polymyxin
B. Both of them display synergy with antibiotics with
intracellular targets, which can at least partially be attributed
to increased outer membrane permeability.175,181,182 Many
other outer membrane-permeabilizing agents are known, for
example, chelators like EDTA, metal ions, and certain
antimicrobial peptides, but many of these have little clinical
promise.183−188 However, several compounds have recently
been described that could make the step into clinical practice
in the future. For example, the antiprotozoal drug pentamidine
has been identified as an outer membrane-permeabilizing
agent. It was shown to potentiate the activity of typical Gram-
positive-only drugs against Gram-negative bacteria in vitro and
in a systemic Acinetobacter baumannii mouse infection model.
Importantly, this activity was retained in colistin-resistant
strains.189,190 Since pentamidine has already been in clinical
use for the treatment of trypanosomiasis, leishmaniasis, and
babesiosis since 1937, its safety and side effects have been
extensively assessed. Recent efforts have yielded lipophilic
vancomycin analogues that were able to permeabilize both the
inner and outer membrane of Gram-negative bacteria while
retaining their ability to inhibit peptidoglycan activity.191
Attempts to fuse outer membrane-penetrating peptide
sequences to the lantibiotic nisin, which by itself is not active
against Gram-negative bacteria due to its inability to reach its
inner membrane target, have resulted in hybrid molecules with
significantly increased anti-Gram-negative activity.192,193 A
similar approach is the hybridization of antibiotics with the
aminoglycoside tobramycin.194 Tobramycin is known as a
ribosome inhibitor but at higher concentrations primarily
attacks and permeabilizes the outer membrane.195,196 It has
been conjugated with efflux pump inhibitors,197 quino-
lones,198,199 and the chelator cyclam.200 The resulting
conjugates turned out to be potent antibiotic adjuvants and
increased the activity of tetracyclines, fluoroquinolones, and β-
lactams against Gram-negative bacteria by increasing uptake
and limiting efflux. This is achieved by a multifaceted
mechanism involving outer membrane permeabilization,
impairment of efflux pumps, and depolarization of the inner
membrane.117,194,197−200 Similar results have been obtained for
tobramycin dimers.201
Another very interesting example are short peptide
sequences derived from the cell cycle proteins FtsA and
MreB from E. coli. These proteins bind to the cytoplasmic
membrane with an amphipathic α helix motif. Peptides derived
from these membrane-anchoring sequences not only display
potent activity against E. coli and other Gram-negative bacteria
but also significantly increase their outer membrane perme-
ability.186,202,203
Few compounds are known that selectively permeabilize the
outer membrane, and most known compounds also permea-
bilize the inner membrane. Such dual membrane activity can
often be a sign for poor selectivity for bacteria, and side effects
are likely. This is, for example, the case for colistin and
polymyxin B and the reason why they are only employed as the
last resort antibiotics for otherwise resistant infec-
tions.98,204−206 However, colistin nonapeptide and polymyxin
B hepta-, octa-, and nonapeptide are derivatives of these
compounds that retain their membrane-permeabilizing but not
antibacterial activity, indicating high selectivity.184 Such
derivatives, particularly polymyxin B nonapeptide, have been
shown to act as strong potentiators of antibiotics with
Figure 3. Mechanisms of synergy. (A) Targeting the same molecule
(here, plectasin in red−yellow and dalbavancin in green−blue), (B)
targeting the same pathway (here, plectasin in red−yellow and
moenomycin in green−blue), (C) targeting a related process (here,
LL-37 in green−blue and teicoplanin in red−yellow), and (D)
improving target accessibility (here, colistin in red−yellow and
minocycline in green−blue).
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otherwise poor anti-Gram-negative activity.184,207,208 At the
same time, it is much less toxic than full-length polymyxin
B.184,209,210 While these properties have been demonstrated by
many different studies, it is not used for combination therapy
in the clinic.211 However, a polymyxin derivative with similar
properties as polymyxin B nonapeptide, NAB741, has been
developed and successfully passed its first phase I clinical
trial.211 Compounds like polymyxin B nonapeptide or NAB741
hold great promise as potentiators of a wide range of
antibiotics that would otherwise be ineffective against Gram-
negative infections. It remains exciting to see how this type of
compound proceeds in future clinical trials.
Sensitizers. A different strategy to enhance the perform-
ance of existing antibiotic drugs is to sensitize bacteria to their
action. This can be achieved by inhibiting bacterial stress
response systems that allow bacteria to adapt and survive
antibiotic exposure (Figure 4B). Many studies on bacterial
stress responses have proposed this as an option for future
drug development, yet this has almost never been pursued.
One exception is the bacterial SOS response to DNA damage.
Figure 4. Mechanisms of resistance-breaking and antibiotic-potentiating compounds. (A) Cell envelope permeabilizers, (B) antibiotic sensitizers,
(C) β-lactamase inhibitors, (D) inhibitors of aminoglycoside-modifying enzymes, (E) efflux pump inhibitors, and (F) biofilm inhibitors. red−
yellow: antibiotic; magenta−turquoise: potentiator.
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DNA damage is sensed by the RecA protein, which induces
autoproteolysis of the LexA repressor, leading to derepression
of DNA repair genes. It has been shown that genetically
impairing this stress response mechanism leads to reversion of
quinolone resistance in E. coli.212 Few inhibitors of DNA repair
have been verified so far. For example, p-coumaric acid was
found to interfere with the DNA-binding ability of RecA in
Listeria monocytogenes and increased the activity of cipro-
floxacin against this pathogen.213 Another study found that
zinc inhibits the ability of RecA to bind to single-stranded
DNA, suggesting a potential application for zinc ionophores.214
However, the effectivity and cytotoxicity of zinc ionophores
would depend on the external zinc concentration,215 which
may limit this approach to topical applications or targeted drug
delivery and release approaches. A large-scale screen for
inhibitors of LexA autoproteolysis has yielded promising lead
structures for the inhibition of this step of SOS response
activation.216 Similarly, IMP-1700, a rationally designed
inhibitor of DNA repair, was later verified to target the
AddAB DNA repair complex and sensitized multidrug-resistant
S. aureus to ciprofloxacin.217
Another example for this strategy was identified by a
transposon screen for increased tobramycin sensitivity in
Pseudomonas aeruginosa. This screen identified the two-
component stress response system AmgRS as a potential
target for combination therapy with aminoglycoside anti-
biotics.218 It was later found that the RNA polymerase
inhibitor rifampicin was also a potent inhibitor of this stress
response system and potentiated the activity of aminoglyco-
sides like tobramycin, amikacin, gentamycin, and neomycin
against P. aeruginosa.219,220
A multitude of stress response systems have been identified
that play a role for antibiotic adaptation and resistance, yet
little effort has been put into identifying inhibitors of these
systems to be used as antibiotic potentiators. In view of the
urgent need for novel antibacterial strategies, this possibility
deserves more attention.
Resistance Breakers. A similar strategy, yet much more
exploited, is the direct targeting of bacterial resistance
mechanisms (Table 4).
The most prominent example for this is the inhibition of β-
lactamase activity234 (Figure 4C). Having pioneered the field,
it was the first resistance-breaking strategy to be applied in the
clinic. It is also the only combination of antibiotic and
potentiator in current clinical use apart from synergistic
combinations with the outer membrane-permeabilizing pep-
tides colistin and polymyxin B. The oldest combination of β-
lactam antibiotic and β-lactamase inhibitor is amoxicillin−
clavulanate, which was approved for clinical use in 1981. It is
still in use today and remains the only one that is orally
available.235 Since then, several other β-lactamase inhibitors
have been identified, and eight combinations are currently on
the market: amoxicillin−clavulanate, ticarcillin−clavulanate,
ampicillin−sulbactam, cefoperazone−sulbactam, piperacillin−
tazobactam, ceftolozane−tazobactam, ceftazidime−avibactam,
and Meropenem−vaborbactam.221,235 Several other combina-
tions are in different stages of clinical development.221
A similar strategy is the inhibition of aminoglycoside-
modifying enzymes, which are responsible for the majority of
cases of aminoglycoside resistance (Figure 4D). Different
enzymes have been described that acetylate different sites of
aminoglycoside antibiotics,236 some of which are inhibited by
Cu2+, Zn2+, and Cd2+ ions.237 Inhibitors of these enzymes have
been identified by molecular docking studies with virtual
compound libraries and by screening libraries for in vitro
enzyme inhibition.222,238,239 One of these has been confirmed
to restore the activity of amikacin against a resistant
Acinetobacter baumannii strain.222 However, none of these
compounds is close to clinical development at the present
time.
The most important intrinsic resistance mechanism, next to
the outer membrane permeability barrier, is constituted by
antibiotic efflux pumps. Particularly, Gram-negative bacteria
possess different multidrug efflux pumps that can export a wide
variety of antibiotics and antimicrobial molecules. The most
prominent efflux pump type is the Gram-negative-specific
resistance-nodulation-division (RND) superfamily, in partic-
ular the well-characterized AcrAB-TolC pump.240 A wide
variety of antibiotics can be the substrate of these export
systems, and their overexpression leads to high level drug
resistance.240 This makes efflux pumps one of the biggest
challenges in overcoming antibiotic resistance and at the same
time an attractive target for resistance-breaking antibiotic
potentiators (Figure 4E). Since the discovery of the very first
efflux pump inhibitors reserpine and verapamil against the
S. aureus efflux pump NorA in 1991,240 a multitude of
inhibitors have been identified for both Gram-positive and
Gram-negative efflux pumps. Many of them have been found
to increase the activity of drugs, which are normally ineffective
due to active export. These molecules have been extensively
reviewed elsewhere.240−244 Despite these efforts, no efflux
pump inhibitor has advanced to clinical development yet.
Table 4. Examples for Resistance-Breaking Compounds
resistance breaker antibiotic mechanism ref
clavulanatea amoxicilline β-lactamase inhibitor 165, 166
avibactama ceftazidime, ceftaroline, aztreonam β-lactamase inhibitor 221
vaborbactama Meropenem β-lactamase inhibitor 221
tazobactama ceftolozane β-lactamase inhibitor 221
compound 1 amikacin inhibitor of aminoglycoside-modifying enzymes 222
PAβN erythromycin, chloramphenicol efflux pump inhibitor 223
verapamil bedaquiline, ofloxacin efflux pump inhibitor 224, 225
IMP-1700 quinolones sensitizer (SOS response) 212, 217
colistina rifampin permeabilizer 226−228
dispersin B several possible biofilm inhibitor 229−231
dehydrocrepenyc acid several possible inhibitor of horizontal gene transfer 232
streptazolin several possible immunomodulator 233
aCombination in clinical use.
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Common limitations of these molecules appear to be a high
toxicity for mammalian cells, low in vivo efficacy, and
insufficient spectrum coverage.240,245 More research into this
topic is needed to fully understand how multidrug efflux
pumps work and how they synergize with other resistance
mechanisms, such as the outer membrane, to go forward with
effective inhibitor design.
Prevention of Horizontal Gene Transfer. A very
different strategy to target antibiotic resistance is inhibiting
horizontal gene transfer. Target mutations are only one way for
bacteria to become antibiotic resistant. The much more
threatening possibility is the spread of resistance genes that are
encoded on plasmids or other mobile genetic elements within
a bacterial population. This is especially critical for otherwise
slowly occurring resistance mechanisms like enzymatic
resistance.246 Importantly, the human (or animal) microbiota
can act as a reservoir for resistance plasmids that may spread to
pathogenic bacteria during infection. Thus, the administration
of an inhibitor of horizontal gene transfer in combination with
antibiotic treatment could decrease the incidence of resistance
transfer from a reservoir to an infectious strain.247 This is an
interesting concept but remains to be tested in infection
experiments. Several compounds have been identified that
inhibit horizontal gene transfer, yet in the majority of cases,
this activity turned out to be due to secondary effects.248
However, a small number of specific inhibitors have been
found. For example, unsaturated fatty acid species from
tropical fruits and their synthetic derivatives were able to
inhibit the transfer of the most important resistance-related
plasmid types in several Gram-negative pathogens.232,249
Likewise, a mutation of a competence-stimulating peptide
from Streptococcus pneumoniae has resulted in peptide versions
that reduced competence and, thus, horizontal gene trans-
fer.250 As mentioned earlier, zinc was able to inhibit the
bacterial SOS response, which interestingly, also impaired
horizontal gene transfer between enterobacteria.214 Secretion
systems could be a promising target for such molecules as well.
Thus, the inhibition of type IV secretion, which is involved in
conjugative DNA transfer, has been shown to be inhibited by
small peptidomimetic compounds.251 While more research is
needed to verify the feasibility of these approaches in clinical
settings, it is certainly an interesting new combination therapy
strategy that deserves further exploration.
Biofilm Inhibitors. One big problem in the clinic is the
production of biofilms by bacteria like S. aureus and
P. aeruginosa, and biofilm inhibitors are potent potentiators
for antibiotics used against such infections (Figure 4F).
Strategies to prevent biofilm formation or disperse mature
biofilms can commonly be divided into three categories: the
inhibition of adhesion or extracellular matrix production, the
inhibition of quorum sensing, and the dispersion of the
extracellular matrix.252 Several antimicrobial peptides, for
example, LL-37, prevent adhesion of bacterial cells by
inhibiting the initiation of biofilm production.253 Furanones
are structurally similar to the quorum sensing molecule N-acyl-
homoserine-lactone and are thought to competitively inhibit
binding to their cognate transcriptional regulator.253 Several
other analogues of quorum sensing molecules have been
patented, yet studies on their clinical potential are yet to
come.254 The most prominent biofilm-dispersing agent is the
glycoside hydrolase dispersin B, which directly targets the
extracellular matrix.230 Further small molecule inhibitors have
been identified for all these mechanisms.254−257
Biofilm inhibitors are particularly relevant in the context of
medical devices like catheters and of chronic lung infections,
with P. aeruginosa being the most problematic pathogen due to
its high intrinsic antibiotic resistance and the emergence of
totally drug-resistant isolates.258 Several compounds have been
described that could be used against P. aeruginosa biofilms.
Interestingly, biofilm-degrading enzymes have been shown to
remain active when immobilized on a surface, suggesting future
applications in medical device technologies.259 Short glycans
have been shown to disrupt P. aeruginosa biofilms and
subsequently increase the efficacy of antibiotics against it.260
The small peptide 1018 targets the stringent response
(p)ppGpp signaling, which is involved in biofilm formation,
and acts as a potent biofilm-dispersing agent not only for
P. aeruginosa but also for other pathogens including Klebsiella
pneumoniae and S. aureus.261 Peptide 1018 also resulted in
decreased virulence of P. aeruginosa in a murine skin infection
model.262 Similarly, small molecule quorum sensing inhibitors
have been shown to increase the efficacy of tobramycin against
P. aeruginosa in a foreign-body infection model in mice.263
Micafungin, which inhibits the synthesis of the pseudomonal
cell wall component 1,3-β-D-glucan, was demonstrated to
prevent P. aeruginosa biofilm formation and improved the
outcome of antibiotic therapy in P. aeruginosa-infected mice,
particularly when combined with the fluoroquinolone levo-
floxacin.264 Interestingly, when the fatty acid synthesis
inhibitor triclosan, which has been commonly used in hygiene
products like toothpaste, was applied together with amino-
glycosides like tobramycin, a strong antibiofilm activity was
observed. Neither of these compounds have an effect on
biofilms by themselves, and the mechanism behind this
adjuvant activity is unknown.265 So far, no biofilm inhibitor
has made the transition to the clinic, yet a number of
preclinical studies show the promise of using such agents as
antibiotic potentiators in the future.
Multidrug Approaches. Combination therapy approaches
may involve more than two compounds. This is, for example,
very common in tuberculosis treatment regimes, which often
consist of a combination of rifampicin, isoniazid, ethambutol,
and pyrazinamide266 but has also been employed for other
bacterial infections.267 A newly emerging approach is the
combination of an antibiotic with more than one potentiator.
This has, for example, been explored for the combination of β-
lactams with β-lactamase inhibitors and permeabilizers such as
dimeric tobramycin and tobramycin−cyclam.200,201 However,
such combinations are not currently used in the clinic.
Challenges of Combination Therapy. To date, anti-
biotic combination therapy is rather a last resort for severe
infections than a standard therapy option. It is normally only
employed for infections with multiresistant bacteria that
cannot be treated with monotherapy, for latent infections
like tuberculosis, or for antibiotics that have a high risk of
encountering resistance when applied alone, such as
trimethoprim−sulfonamide or β-lactam−β-lactamase combi-
nations. Just as multitarget antibiotics are more effective than
single-target antibiotics,267 combination therapy is superior
over monotherapy in terms of patient outcomes, at least when
it comes to infections with multiresistant pathogens.268 The
current developments on antibiotic adjuvants have shown great
promise for new combination strategies being added to our
clinically available repertoire soon. However, combination
therapies also face challenges.
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One important limitation is the development of clinically
useful formulations and treatment regimes. Finding the right
dosing, treatment intervals, and total treatment duration can
already be challenging for single drugs and gets much more
complicated with each additional drug added to the regime,
since each individual drug has its own pharmacodynamic and
-kinetic properties and its own side effects. Matching these to
elicit the desired outcome in patients can be a serious
challenge.267,269 A solution for this limitation could be
antibiotic hybrids as discussed in Designer Dual-Target
Compounds. However, hybrid molecules may encounter
other challenges like solubility and uptake.125
Another risk of combination therapy is antimicrobial
resistance. While many empirical studies have found that
drug combinations suppress resistance,198,269−276 other studies
have warned that under certain conditions antibiotic
combinations might even promote faster resistance develop-
ment. This is a particular concern for synergistic drug
combinations. While they allow one to lower the dose and
thus reduce side effects,277,278 they come with an inherent risk
of treatment failure through resistance: If resistance to one
drug occurs, synergistic effects are lost, resulting in the low-
dose exposure to a single antibiotic.279−283 Even with
nonsynergistic antibiotic combinations, the risk for increased
resistance development is evident. A recent study found that
the development of tolerance, i.e., the ability of bacteria to
survive longer under antibiotic exposure without changing the
antibiotic’s minimal inhibitory concentration, to one drug may
promote the transmission of resistance to the second drug.284
These unwanted effects of combination treatments seem to be
due to the prolonged survival of bacteria and their exposure to
sublethal antibiotic concentrations. Therefore, the concept of
“hitting them fast and hard”, which has been proposed to be a
key to successful antibiotic treatment, should be paid particular
attention in combination regimes, even if lowering drug doses
can be tempting to reduce adverse effects.6,276
■ CONCLUSION
Many fascinating approaches have been and are currently being
developed to target multiple molecules in bacterial cells. From
antibiotics that have multiple downstream effects, true
multitargeting compounds, and dual-activity hybrid molecules
to combination approaches with antibiotic adjuvants, all of
these strategies have shown a certain promise and give hope for
one to see light at the end of the tunnel of antibiotic
development. Recent research gives the concept of poly-
pharmacology another dimension by designing antibiotic
adjuvants that possess multiple mechanisms themselves, such
as outer membrane permeabilization and efflux pump
inhibition, which synergistically increase the intracellular
antibiotic concentration.197 While more research is needed to
truly understand the complex mechanisms underlying some of
these multiple activities, they have already taught us one
important thing, namely, that we should not shy away from
complex mechanisms and multiple targets but try to exploit
their full potential for future drug development.
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